EP0792350A1 - Regulation of neural stem cell proliferation - Google Patents
Regulation of neural stem cell proliferationInfo
- Publication number
- EP0792350A1 EP0792350A1 EP95936393A EP95936393A EP0792350A1 EP 0792350 A1 EP0792350 A1 EP 0792350A1 EP 95936393 A EP95936393 A EP 95936393A EP 95936393 A EP95936393 A EP 95936393A EP 0792350 A1 EP0792350 A1 EP 0792350A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- stem cell
- cells
- proliferation
- neural stem
- egf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000001178 neural stem cell Anatomy 0.000 title claims abstract description 56
- 230000004663 cell proliferation Effects 0.000 title claims abstract description 19
- 230000033228 biological regulation Effects 0.000 title abstract description 6
- 210000000130 stem cell Anatomy 0.000 claims abstract description 97
- 238000000034 method Methods 0.000 claims abstract description 33
- 230000001105 regulatory effect Effects 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 238000000338 in vitro Methods 0.000 claims abstract description 18
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 230000035755 proliferation Effects 0.000 claims description 58
- 230000002062 proliferating effect Effects 0.000 claims description 45
- 210000003169 central nervous system Anatomy 0.000 claims description 42
- 210000002569 neuron Anatomy 0.000 claims description 25
- 229920002971 Heparan sulfate Polymers 0.000 claims description 19
- 210000001130 astrocyte Anatomy 0.000 claims description 19
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 16
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 16
- 230000001537 neural effect Effects 0.000 claims description 16
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 14
- 229930002330 retinoic acid Natural products 0.000 claims description 14
- 229960001727 tretinoin Drugs 0.000 claims description 14
- 230000000692 anti-sense effect Effects 0.000 claims description 13
- 210000004248 oligodendroglia Anatomy 0.000 claims description 13
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 12
- 210000004556 brain Anatomy 0.000 claims description 10
- 208000012902 Nervous system disease Diseases 0.000 claims description 9
- 108091008794 FGF receptors Proteins 0.000 claims description 8
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 8
- 102000015696 Interleukins Human genes 0.000 claims description 7
- 108010063738 Interleukins Proteins 0.000 claims description 7
- 229940047122 interleukins Drugs 0.000 claims description 7
- 102000001301 EGF receptor Human genes 0.000 claims description 6
- 108060006698 EGF receptor Proteins 0.000 claims description 6
- 208000029028 brain injury Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 102000007299 Amphiregulin Human genes 0.000 claims description 4
- 108010033760 Amphiregulin Proteins 0.000 claims description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 4
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 4
- 231100000241 scar Toxicity 0.000 claims description 4
- 208000020431 spinal cord injury Diseases 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 230000009772 tissue formation Effects 0.000 claims description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 101150092509 Actn gene Proteins 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 105
- 239000003181 biological factor Substances 0.000 abstract description 20
- 239000002243 precursor Substances 0.000 abstract description 15
- 238000001727 in vivo Methods 0.000 abstract description 11
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 64
- 101800003838 Epidermal growth factor Proteins 0.000 description 63
- 229940116977 epidermal growth factor Drugs 0.000 description 63
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 60
- 210000001519 tissue Anatomy 0.000 description 49
- 208000027418 Wounds and injury Diseases 0.000 description 24
- 230000006378 damage Effects 0.000 description 21
- 239000003102 growth factor Substances 0.000 description 21
- 230000004044 response Effects 0.000 description 21
- 208000014674 injury Diseases 0.000 description 19
- 239000002609 medium Substances 0.000 description 16
- 210000003061 neural cell Anatomy 0.000 description 15
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 14
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 102000037983 regulatory factors Human genes 0.000 description 14
- 108091008025 regulatory factors Proteins 0.000 description 14
- 108010025020 Nerve Growth Factor Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 206010018341 Gliosis Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 102000015336 Nerve Growth Factor Human genes 0.000 description 10
- 229940053128 nerve growth factor Drugs 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 9
- 210000000278 spinal cord Anatomy 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 208000025966 Neurological disease Diseases 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 6
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 6
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 6
- 230000007387 gliosis Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 5
- 206010061431 Glial scar Diseases 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000115 thoracic cavity Anatomy 0.000 description 5
- 108010059616 Activins Proteins 0.000 description 4
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 4
- 102100026818 Inhibin beta E chain Human genes 0.000 description 4
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 4
- 102000008730 Nestin Human genes 0.000 description 4
- 108010088225 Nestin Proteins 0.000 description 4
- 108091081021 Sense strand Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000000488 activin Substances 0.000 description 4
- -1 bFGF Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 210000005055 nestin Anatomy 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000001228 trophic effect Effects 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000043168 TGF-beta family Human genes 0.000 description 3
- 108091085018 TGF-beta family Proteins 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 210000004289 cerebral ventricle Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- 210000004705 lumbosacral region Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000008458 response to injury Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102100028652 Gamma-enolase Human genes 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 101100117488 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mip-1 gene Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000003522 acrylic cement Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 101150022753 galc gene Proteins 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000005155 neural progenitor cell Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000033912 thigmotaxis Effects 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000012411 Intermediate Filament Proteins Human genes 0.000 description 1
- 108010061998 Intermediate Filament Proteins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 102100023487 Lens fiber major intrinsic protein Human genes 0.000 description 1
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 108010047660 Mitochondrial intermediate peptidase Proteins 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011797 cavity material Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VIEXQFHKRAHTQS-UHFFFAOYSA-N chloroselanyl selenohypochlorite Chemical compound Cl[Se][Se]Cl VIEXQFHKRAHTQS-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004055 fourth ventricle Anatomy 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000000461 neuroepithelial cell Anatomy 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000009237 prenatal development Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 210000000954 sacrococcygeal region Anatomy 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000211 third ventricle Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
Definitions
- stem cells In actively dividing tissues, such as bone marrow which gives rise to blood cells, specialized cells, known as stem cells, are present.
- the critical identifying feature of a stem cell is its ability to exhibit self-renewal or to generate more of itself.
- the simplest definition of a stem cell would be a cell with the capacity for self- maintenance.
- a more stringent (but still simplistic) definition of a stem cell is provided by Potten and Loeffler [Development, 110: 1001 (1990)] who have defined stem cells as "undifferentiated cells capable of a) proliferation, b) self- maintenance, c) the production of a large number of differentiated functional progeny, d) regenerating the tissue after injury, and e) a flexibility in the use of these options.
- Stem cells divide, generating progeny known as precursor cells.
- Precursor cells comprise new stem cells and progenitor cells.
- the new stem cells are capable of dividing again, producing more stem cells, ensuring self-maintenance, and more progenitor cells.
- the progenitor cells are capable of limited proliferation, where all of their progeny ultimately undergo irreversible differentiation into amitotic, functional cells.
- FIG. 1 illustrates the relationship between stem cells, progenitor cells and differentiated cells.
- the role of stem cells is to replace cells that are lost by natural cell death, injury or disease.
- the presence of stem cells in a particular type of tissue usually correlates with tissues that have a high turnover of cells. However, this correlation may not always hold as stem cells are thought to be present in tissues, such as the liver [Travis, Science, 259: 1829 (1989)] that do not have a high turnover of cells.
- the best characterized stem cell system is the hematopoietic stem cell.
- Evidence suggests that a single hematopoietic stem cell, located in bone marrow, is able to give rise, via a series of progenitor cells, to all of the blood cell lineages.
- US Patent 5,061 ,620, issued October 29, 1991 provides a means for isolating, regenerating and using the hematopoietic stem cell.
- hematopoietic stem cells are active at many sites, including the fetal yolk sac, bone marrow, liver and spleen, Shortly before birth the bone marrow takes over as the primary site of hematopoiesis.
- the hematopoietic stem cells in the liver and spleen become quiescent and do not resume production of blood cells unless hematopoietic stem cell activity in the bone marrow is suppressed or widespread destruction of blood cells occurs.
- the differentiated cells of the adult mammalian CNS exhibit little or no ability to enter the mitotic cycle and generate new neural tissue — essentially all neurogenesis occurs during the prenatal and immediate post-natal p riods W hile it is believed that there is a limited and slow turnover ot astrocytes [ ⁇ rr c ⁇ al , J Co p. Neurol. , 150: 169 (1971)] and that progenitor cells which can give rise to oligodendrocytes are present [Wolsqijk and Noble, Development, 105: 386-698 (1989)], the generation of new neurons does not normally occur.
- Rats exhibit a limited ability to generate new neurons in restricted adult brain regions such as the dentate gyrus and olfactory bulb [Kaplan, J. Comp. Neurol. , 195: 323 (1987); Bayer, S.A, NY. ⁇ cacl. Set. , 457: 163- 172 ( 1985)] but this does not apply to all mammals; and the generation of new neurons in adult primates does not occur [Rakic, P. , Science, 227: 1054 (1985)].
- This inability to produce new neuronal cells in most mammals (and especially primates) may be advantageous for long-term memory retention; however, it is a distinct disadvantage when the need to replace lost neuronal cells arises due to injury or disease.
- hematopoietic stem cells survival, expansion and proliferation of the hematopoietic stem cells, and stem cell systems in the liver, intestines and skin have been shown to be under the control of a number of different trophic factors.
- growth factors such as erythropoietin and the glycoprotein CSF (colony-stimulating factor) and various interleukins have been identified as factors which regulate stem cell function [Metcalf, D. , Bioassays, 14(12): 799-805 (1992)] .
- PDGF platelet derived growth factor
- CNTF ciliary neurotrophic factor
- bFGF basic f ⁇ broblast growth factor
- EGF epidermal growth factor
- TGF ⁇ transforming growth factor alpha
- NGF nerve growth factor
- 0-2A cell a type of embryonic neural progenitor cell, known as the 0-2A cell, gives rise to oligodendrocytes and type-2 astrocytes.
- the 0-2 A cell divides and after a few divisions differentiates into oligodendrocytes.
- CNTF and substrate factors rather than PDGF
- bFGF produces a two-told increase in the proliferation of embryonic progenitor cells which develop into neurons [Gensberger et at. FEB Lett. , 217: 1 -5 ( 1987)].
- Cattaneo and McKay (1990) showed that growth factors added together or in sequential fashion will elicit novel responses not seen when the factors are added individually.
- NGF stimulated the proliferation of embryonic neuroblasts to produce neurons only after they have been previously primed with bFGF [Cattaneo, E. and McKay, R. , Nature, 347: 762-765 ( 1990)].
- bFGF has also been shown to influence the expression of the PDGF receptor and to block the differentiation of the 0-2A progenitor cell when exposed to PDGF [McKinnon et al. , Neuron, 5: 603-614 ( 1990)].
- EGF or TGF ⁇ show some mitogenic effects on embryonic retinal neuroepithelial cells grown in culture, resulting in progenitor cells which, in the continued presence of the growth factors, give rise to neurons but not to glial cells [Anchan et al.. Neuron, 6: 923-936 (1991)]. In the same study, neurons and Miiller cells are reported to occur in cultures derived from postnatal rat neuroepiihelium.
- CNS disorders encompass numerous afflictions such as neurodegenerative diseases (e.g. Alzheimer's and Parkinson's), acute brain injury (e.g. stroke, head ⁇ njur ⁇ , cerebral palsy) and a large number of diseases associated ith CNS d ⁇ stun t ⁇ on (e.g. depression, epilepsy, and schizophrenia)
- neurodegenerative diseases e.g. Alzheimer's and Parkinson's
- acute brain injury e.g. stroke, head ⁇ njur ⁇ , cerebral palsy
- a large number of diseases associated ith CNS d ⁇ stun t ⁇ on e.g. depression, epilepsy, and schizophrenia
- ⁇ ears neurodegeneramc disease has become an important concern due to the expanding elderl ⁇ population which is at greatest risk for these disorders.
- CNS dysfunction with respect to the number of affected people
- CNS dysfunction are not characterized by a loss of neural cells but rather by an abnormal functioning of existing neural cells. This may be due to inappropriate firing of neurons, or the abnormal synthesis, release, and processing of neurotransmitters.
- An emerging technology for treating neurological disorders entails the transplantation of cells into the CNS to replace or compensate for loss or abnormal functioning of the host's nerve cells. While embryonic CNS cells given the best results in human trials [Winder et al. , New Eni;. J. Med. , 327: 1556 ( 1992)] and are the preferred donor tissue, ethical and political considerations, as well as the availability of sufficient quantities of tissue, limit the use ⁇ i these cells. Other types of donor tissue for use in the treatment of CNS disorders are being developed. These include: genetically modified neural cell lines [Renfranz et al.
- transplantation approaches represent a significant improvement over currently available treatments for neurological disorders, the technology has not yet been perfected.
- some cell types fail to integrate with host CNS tissue.
- the use of non-neuronal primary cell cultures limits the ability of the transplanted material to make connections with the host tissue.
- Immortalized donor cells obtained from primary neural tissue could form connections but the genetic expression of the oncogenes inco ⁇ orated into these transformed cells is hard to control and could produce tumors and other complications.
- Donor and host could result in the rejection of the implanted cells.
- the transplanted cells can result in tumor formation or pass infectious agents from the donor tissue to the host.
- Gage et al. in US Patent 5,082,670, disclose a method of treating defects, disease or CNS cell damage by grafting genetically modified neural cells into the appropriate CNS regions.
- the donor cells disclosed in this patent were obtained from non-neuronal primary cultures but it was suggested that genetically transformed neural cell lines could be used. These donor cell sources are inherently problematic.
- Gage et al. recognize the limitations imposed by the donor cells used in their technique and acknowledge that there is a ".. paucity of replicating non-transformed cell-culture systems... " They also recognize "the refractoriness of non-replicating neuronal cells to viral infection.
- the multipotent neural stem cells which are now known to be present in the brains of mammals throughout their lives [Reynolds and Weiss, Science, 255- 1707 (1992)], provide a source of non-transformed neural cells which can be stimulated, in the presence of a growth factor such as epidermal growth factor, to become mitotically active.
- the neural stem cells can be induced to proliferate and can provide large quantities of undifferentiated neural cells, which are capable of differentiation into the major types of neural cells and can be transplanted, genetically modified and then transplanted, or used for drug screening or other purposes.
- gliosis In response to injury of brain or spinal cord tissue, gliosis occurs It is thought that the glial scar which results from this process may prevent neuronal axons from reestablishing connections across the injury region, thus preventing the restoration of function.
- Astrocytes which proliferate both at the wound sue and some distance away from the immediate vicinity of the wound are the principle cellular components of a glial scar (Reier, PJ. Astrocytes vol. 3: 263-323 ( 1986)). Proliferation of neural stem cells and their progeny in response to injury may be a factor in the development of gliosis Neural repair could be enhanced if the extent of gliosis at the injury site could be reduced.
- compositions for the in vivo regulation of the proliferation ol CNS stem cells
- the compositions comprise specific biological lactors, such as grow th factors or combinations of such factors, which are intused into the ventricular system ot the CNS to regulate stem cell proliferation.
- a method of regulating the in vitro proliferation ot a multipotent neural stem cell and/or the proliferation of progeny of said neural stem cell comprises the steps of dissociating mammalian neural tissue containing at least one multipotent neural stem cell capable of producing progeny that are capable of differentiating into neurons, astrocytes and oligodendrocytes, and proliferating the multipotent neural stem cell in a culture medium containing at least one proliferative factor that induces stem cell proliferation and a regulatory factor that regulates proliferation of the multipotent neural stem cell and/or proliferation of the progeny of the multipotent neural stem cell.
- a method and compositions for regulating the in vivo proliferation of a multipotent neural stem cell and/or the proliferation of progeny of said neural stem cell are described.
- the method comprises the steps of delivering to the ventricular regions of a mammal a therapeutic composition comprising at least one factor that has a regulatory effect on the proliferation of a multipotent neural stem cell and or the proliferation of the progeny of the multipotent neural stem cell.
- the proliferative factor is bFGF and the regulatory factor is EGF or heparan sulfate which increase the rate of proliferation of stem cell progeny.
- a therapeutic composition comprising a factor or combination of factors which inhibit the proliferation ⁇ i neural stem cells is administered //; V ⁇ ' VY to reduce the proliferation of the cells.
- FIG. 1 A schematic diagram illustrating the proliferation of a multipotent neural stem cell.
- A In the presence of a proliferative factor the stem cell divides and gives rise to a sphere of undifferentiated cells composed of more stem cells and progenitor cells.
- B When the clonally derived sphere of undifferentiated cells is dissociated and plated as single cells, on a non-adhesive substrate and in the presence of a proliferative factor, each stem cell will generate a new sphere.
- C If the spheres are cultured in conditions that allow differentiation, the progenitor cells differentiate into neurons, astrocytes and oligodendrocytes.
- FIG. 1 A schematic diagram illustrating the proliferation of a multipotent neural stem cell.
- FIG. 3 Graph showing the number of neurospheres generated from primary cells derived from the cervical, thoracic, and lumbar regions of adult mice spinal cord in the presence of 20 ng/ml EGF + 20 ng/ml FGF or 20 ng/ml FGF + 2 ⁇ g/ml heparan sulfate.
- neural stem cell or "central nervous system (CNS) stem cell” refers to a relatively quiescent, undifferentiated stem cell from neural tissue that is capable of proliferation, giving rise to more neural stem cells (thus ensuring self-maintenance) and to progenitor cells.
- multipotent refers to a neural stem cell that is capable ot producing progeny that give rise to each of the major types of differentiated neural cells, i.e.
- an undifferentiated cell that gives rise to two types of differentiated cells for example, the O-2A cell, which gives rise to oligodendrocytes and astrocytes. is termed “bipotent” , and one that gives rise to only one type of differentiated cell is termed “unipotent”.
- progenitor cell also refers to an undifferentiated cell derived from a neural stem cell but differs from a stem cell in that it has limited ability to proliferate and does not maintain itself.
- Each of a neural progenitor cell's progeny will, under appropriate conditions, differentiate into a neuron, astrocyte (type I or type II) or oligodendrocyte. Oligodendrocytes are differentiated glial cells that form the myelin surrounding axons in the central nervous system (CNS).
- CNS central nervous system
- Oligodendrocytes have the phenotype galactocerebroside ( + ), myelin basic protein (+), and glial fibrillary acidic protein (-) [GalC(+), MBP(+), GFAP(-)].
- Neurons are differentiated neuronal cells that have the phenotype neuron specific enolase (+), neurofilament (+), microtubule associated protein or Tau-1 (+) [NSE(+), NF (+), MAP-2 (+), or Tau-1 (+)].
- Astrocytes are differentiated glial cells that have the phenotype GFAP( + ), GalC(-), and MBP(-).
- the CNS stem cell is capable of self- aintenance and generating a large number of progeny including new stem cells and progenitor cells capable of differentiation into neurons, astrocytes and oligodendrocytes.
- CNS stem cells can be isolated and cultured from any pre- or post-natal mammalian CNS tissue by the methods described by Rey nolds and W eiss [Saern c. 255: 1707, ( 1992)], the published PCT applications referenced e. and in Example 1 , below .
- Multipotent CNS stem cells occur in a oi CNS regions. including the conus medullaris, cervical, thoracic and lumbar regions of the spinal cord, the brain stem, striatum and hypothalamus.
- the neural stem cells can be obtained from tissue from each of these regions and induced to divide in vitro, exhibiting self-maintenance and generating a large number of progeny which include neurons, astrocytes and oligodendrocytes.
- the multipotent neural stem cell is obtained from neural tissue and grown in a culture medium which is preferably serum-free and which may comprise any combination of substances known to support the survival of cells.
- a suitable serum-free culture medium herein after referred to as "Complete Medium”, comprises Dulbecco's modified Eagle's medium (DMEM) and F- 12 nutrient mixture (Gibco) (1 : 1), glucose (0.6%), glutamine (2 mM), sodium bicarbonate (3 mM), HEPES (4-[2-hydroxyethyI]- l -p ⁇ peraz ⁇ neethanesulfon ⁇ c acid) buffer (5 mM) and a defined hormone mix and salt mixture (10% ; available from Sigma), used to replace serum, which comprises insulin (25 ⁇ g/ml), transferrin (100 ⁇ g/ml), progesterone (20 ⁇ M), putrescine (60 ⁇ M), and selenium chloride (30 nM).
- At least one biological factor that induces multipotent stem cell proliferation
- biological factor refers to a biologically active substance that is functional in CNS cells, such as a protein, peptide, nucleic acid, growth factor, steroid or other molecule, natural or man-made, that has a growth, proliferative, differentiative, trophic, or regulatory effect (either singly or in combination with other biological factors) on stem cells or stem cell progeny.
- biological factors include growth factors such as acidic and basic fibroblast growth factors (aFGF, bFGF), epidermal grow th tactor (EGJ-) and EG1 - like ligands, transforming growth factor alpha (TGF ⁇ ), insulin-like growth factor (IGF-1), nerve growth factor (NGF), platelet-derived growth factor (PDGF), and transforming growth factor betas (TGF/3); trophic factors such as brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF). and glial-de ⁇ ved neurotrophic factor (GDNF); regulators of intracellular pathw ay associated w ith grow th factor activity such as phorbol 12-my ⁇ state 13-acetate. staur ⁇ spormc.
- aFGF, bFGF epidermal grow th tactor
- TGF ⁇ transforming growth factor alpha
- IGF-1 insulin-like growth factor
- NGF nerve growth factor
- PDGF platelet-derived growth factor
- TGF/3
- hormones such as a n .iU ⁇ i ⁇ ⁇ KHI OPU I le.easni - hormone (TRH); various proteins and polypeptides such as interleukins.
- BMP-2 bone morphogemc protein
- MlP-l ⁇ macrophage inflammatory proteins
- MIP-1B and MIP-2 macrophage inflammatory proteins
- oligonucleotides such as antisense strands directed, for example, against transcripts for EGF receptors, FGF receptors, and the like
- hepa ⁇ n-like molecules such as heparan sulfate
- TNF ⁇ J tumor necrosis factor alpha
- proliferative factors Biological factors, such as EGF and bFGF, that individually have a proliferative effect on multipotent neural stem cells are herein referred to as "proliferative factors".
- proliferative factors bind to a cell-surface receptor, resulting in the induction of proliferation.
- Preferred proliferative factors include EGF, amphiregulin, aFGF, bFGF, TGF ⁇ , and combinations of these and other biological factors, such as heparan sulfate.
- a particularly preferred combination for inducing the proliferation of neural stem cells is EGF and bFGF.
- the proliferative factors are usually added to the culture medium at a concentration in the range of about 10 pg/ml to 500 ng/ml, preferably about 1 ng/ml to 100 ng/ml.
- concentration in the range of about 10 pg/ml to 500 ng/ml, preferably about 1 ng/ml to 100 ng/ml.
- concentration for EGF, aFGF and bFGF is about 20 ng/ml of each proliferative factor.
- the stem cells may be cultured in any culture vessels, for example 96 well plates or culture flasks. In the presence of a proliferation-inducing growth factor or combination of factors a multipotent neural stem cell divides, giving rise, within 3- 4 days, to undifferentiated stem-cell progeny.
- the stem cell progeny referred to herein as "precursor cells”, include newly generated multipotent stem cells and progenitor cells, ln vitro, the progeny of a single stem cell typically forms a cluster of precursor cells referred to herein as a "neurosphere"; however, culture conditions may be changed (e.g. by providing a treated substrate onto which the proliferating cells adhere) so that the proliferating cells do not form the characteristic neurospheres.
- Precursor cells are not iinmunoreactive for any of the neuronal or glial cell markers, but they are immunoreactive for nestin, an intermediate filament protein found in undifferentiated CNS cells [Lehndahl et al. , Cell, 60: 585-595 ( 1990)].
- the precursor cells within the neurosphere continue to divide resulting in an increase in the size of the neurospheres as a result of an increase in the number of undifferentiated cells [nestin( + ), NF(-), NSE (-), GFAP(-), MBP (-)]. It is possible to passage the precursor cells in the presence of the same growth factors or different growth factors that allow further proliferation to occur without promoting differentiation. Cells can be passaged 30 times or more using proliferative culture methods, resulting in an exponential increase in precursor cell numbers.
- the culture techniques described above for the proliferation of CNS stem cells in vitro can be modified through the use of additional biological factors or combinations of factors which increase, decrease or modify in some other way the number and nature of the precursor cells obtained from the stem cells in response to EGF or other proliferative factors Changes in proliferation are observed by an increase or decrease in the number of neurospheres that form and/or an increase or decrease in the size of the neurospheres (which is a reflection of the rate of proliferation — determined by the numbers of precursor cells per neurosphere).
- regulatory factor is used herein to refer to a biological factor that has a regulatory effect on the proliferation of stem cells and/or precursor cells
- a biological factor would be considered a “regulatory factor” if it increases or decreases the number of stem cells that proliferate in vitro in response to a proliferation-inducing growth factor (such as EGF).
- a proliferation-inducing growth factor such as EGF
- the number of stem cells that respond to proliferation-inducing factors may remain the same, but addition of the regulatory factor affects the rate at which the stem cell and stem cell progeny proliferate.
- a proliferative factor may act as a regulatory factor when used in combination with another proliferative factor
- the neurospheres that form in the presence of a combination of bTGF and EGF are significantly larger than the neurospheres that form in the presence ot bFGF alone indicating that the rate of proliferation of stem cells and stem cell progeny is higher
- regulatory factors include heparan sultate. transiormmg grovwh factor beta (TGF ⁇ ), activin bone morphogenic protein (BM P 2 j uhar ⁇ neurotrophic factor (CNTF), retinoic acid, tumor necrosis factor alpha (TNF ⁇ ), macrophage inflammatory proteins (MlP- l ⁇ , MIP-l ⁇ and MIP-2), nerve growth factor (NGF), platelet derived growth factor (PDGF), interleukins, and the Bcl-2 gene product.
- TGF ⁇ transiormmg grovwh factor beta
- BM P 2 j uhar ⁇ neurotrophic factor (CNTF) retinoic acid
- TNF ⁇ tumor necrosis factor alpha
- MlP- l ⁇ , MIP-l ⁇ and MIP-2 nerve growth factor
- NGF nerve growth factor
- PDGF platelet derived growth factor
- interleukins interleukins
- Antisense molecules that bind to transcripts of proliferative factors and the transcripts for their receptors also regulate stem cell proliferation
- Other factors having a regulatory effect on stem cell proliferation include those that interfere with the activation ot the c-fos pathway (an intermediate early gene, known to be activated by EGF), including phorbol 12 my ⁇ state 13-acetate (PMA; Sigma), which up-regulates the c-fos pathway and staurospo ⁇ ne (Research
- CGP-41251 (Ciba-Geigy), which down regulate c- fos expression and factors, such as tyrphostin [Fallon, D et al. , Mol. Cell Bioi , 11(5): 2697-2703 (1991)] and the like, which suppress tyrosine kinase activation induced by the binding of EGF to its receptor.
- Preferred regulatory factors for increasing the rate at which neural stem cell progeny proliferate in response to FGF are heparan sulfate and EGF.
- Preferred regulatory factors for decreasing the number of stem cells that respond to proliferative factors are members of the TGF ⁇ family, interleukins, MIPs, PDGF, BMP-2, TNF ⁇ , retinoic acid (10 ° M) and CNTF.
- Preferred factors for decreasing the size of neurospheres generated by the proliferative factors are members of the TGF ⁇ family, retinoic acid (10 6 M) and CNTF.
- the regulatory factors are added to the culture medium at a concentration in the range of about 10 pg/ml to 500 ng/ml, preferably about 1 ng/ml to 100 ng/ml.
- the most preferred concentration for regulatory factors is about 10 ng/ml.
- the regulatory factor retinoic acid is prepared from a 1 mM stock solution and used at a final concentration between about 0.01 ⁇ M and 100 ⁇ M, preferably between about 0.05 to 5 ⁇ M.
- Preferred for reducing the proliferative effects of EGF or bFGF on neurosphere generation is a concentration of about 1 ⁇ M of retinoic acid.
- Antisense strands can be used at concentrations from about 1 to 25 ⁇ M .
- PMA and related molecules, used to increase proliferation may be used at a concentration of about 1 ⁇ g ml to 500 ⁇ g/ml, preferably at a concentration of about 10 ⁇ g/ml to 200 ⁇ g/ml.
- the glycosaminoglycan, heparan sulfate is a ubiquitous component on the surface of mammalian cells known to affect a variety of cellular processes, and which binds to growth factor molecules such as FGF and amphiregulin, thereby promoting the binding of these molecules to their receptors on the surfaces of cells.
- the precursor cells can be used for transplantation to treat various neurological disorders, as disclosed in PCT applications no. WO 93/01275, WO 94/16718, WO 94/10292, and WO 94/091 19.
- the cells which are to be used for transplantation can be harvested from the culture medium and transplanted, using any means known in the art, to any animal with abnormal neurological or neurodegenerative symptoms, obtained in any manner, including those obtained as a result of chemical, electrical, mechanical or other lesions, as a result of experimental aspiration of neural areas or as a result of disease or aging processes.
- the methods disclosed herein can also be used to test the proliferative or regulatory effects of biological factors on multipotent mammalian neural stem cell proliferation in vitro, prior to using the biological factors for the in vivo regulation of the proliferation of a patient's normally quiescent stem cells.
- the neural stem cells may be obtained from a human with a neurological disorder in order to test the proliferative or regulatory effects of biological factors on dysfunctional, diseased, or injured tissue.
- Therapeutic compositions comprising the regulatory factors can then be prepared for use in the treatment of various neurological disorders, disease, or injury.
- the compositions comprise one or more regulatory factors at the above concentrations in a physiologically acceptable formulation.
- the therapeutic compositions may be administered in vivo to regulate the proliferation of neural stem cells.
- the normally quiescent neural stem cells are located throughout the CNS near ventricular regions.
- Within the forebrain are the lateral (first and second) ventricles.
- the third ventricle is a cav ity of the lower part of the forebrain which is connected to the fourth ventricle located in the hindbrain.
- the central canal continuous with the aforementioned ventricular structures, is the ventricular component of the spinal cord.
- CNS stem cells are located in the tissues lining ventricles offers several advantages for the modification and manipulation of these cells in vivo and the ultimate treatment of various neurological diseases, disorders, and injury that affect different regions of the CNS. Therapy for these can be tailored accordingly so that stem cells surrounding ventricles near the affected region would be manipulated or modified in vivo using the methods described herein.
- the ventricular system is found in nearly all brain regions and thus allows easier access to the affected areas. If one wants to modify the stem cells by exposing them to a composition comprising a growth factor or a viral vector, it is relatively easy to implant a device that administers the composition to the ventricle. For example, a cannula attached to an osmotic pump may be used to deliver the composition.
- the composition may be injected directly into the ventricles. This would allow the migration of the CNS stem cell progeny into regions which have been damaged as a result of injury or disease. Furthermore, the close proximity of the ventricles to many brain regions would allow for the diffusion of a secreted neurological agent by the stem cells or their progeny.
- Gliosis which results in the formation of glial scar tissue, results from damage to CNS tissue.
- the scar tissue is considered to have a major inhibitory effect on axonal outgrowth and the reconnection of severed elements, thus preventing functional recovery following brain or spinal cord injury.
- astrocytes While not the only component of CNS scar tissue, astrocytes are one of the major elements involved. (Reier, PJ. Astrocytes vol. 3: 263-323 ( 1986)). It is a possibility that the gliosis results, at least in part, from the proliferation of previously quiescent stem cells.
- a preferred inhibitory factor is BMP-2.
- Example 1 In vitro proliferation of multipotent CNS stem cells derived from embryonic brain tissue — neurosphere proliferation in response to EGF
- Embryonic day 14 (El 4) CD, albino mice (Charles River) were decapitated and the brain and striata removed using sterile procedure. The tissue was mechanically dissociated with a fire-polished Pasteur pipette into Complete Medium. The cells were centrifuged at 800 r.p.m. for 5 minutes, the supernatant aspirated, and the cells resuspended in Complete Medium for counting. The cells were suspended at a density of 25,000 cells/ml in Complete Medium containing 20 ng/ml EGF.
- neurospheres When the cells were proliferated, within the first 48 hours and by 3-4 days in vitro (DIV), they formed small clusters, known as neurospheres, that lifted off the substrate between 4-6 DIV. The number of neurospheres generated per well were counted and the results were tabulated and compared with the numbers of neurospheres generated in response to EGF after passaging the cells (see example 2) and in response to other biological factors alone, or in combination with EGF (see Example 3).
- Example 2 Passaging of proliferated neurospheres Paradigm 1 : Cells and media were prepared as outlined in Example 1 . Cells were plated at 0.2 x 10 6 cells/ml into 75 c ⁇ r tissue culture flasks (Corning) with no substrate pre-treatment and incubated as outlined in Example I
- the neurospheres were removed, centrifuged at 400 r.p. m. for 2-5 minutes, and the pellet was mechanically dissociated into individual cells with a fire-polished glass Pasteur pipet in 2 mis of Complete Medium.
- Paradigm 2 The methods of Example 1 and Example 2 paradigm 1 were followed except that 20 ng/ml FGF was added to the Complete Medium in place of the EGF.
- Paradigm 3 The methods of Example 1 and Example 2 paradigm 1 were followed except that 20 ng/ml FGF was added to the Complete Medium in addition to the 20 ng/ml EGF that was added.
- Neurospheres obtained after passaging, can be mechanically dissociated and the cells replated in 96 well plates as outlined in Example 1.
- the effects of specific biological factors, or specific combinations of biological factors on the proliferation of neurospheres from cells derived from passaged neurospheres can be determined and compared with results obtained from cells derived from primary tissue.
- Example 3 Assay of striatum-derived neurosphere proliferation in response to various combinations of proliferative and regulatory factors
- Paradigm 1 Primary striatal cells prepared as outlined in Example 1 were suspended in Complete Medium, without growth factors, plated in 96 well plates
- Activin, BMP-2, TGF-/3, IL-2, IL-6, IL-8, MlP- ld, MIP- 1 3, MIP-2 (all obtained from Chiron Corp.), TNF ⁇ , NGF (Sigma), PDGF (R&D Systems), EGF and CNTF (R. Dunn and P. Richardson, McGill University) were made up in separate flasks of compete medium to a final concentration of 0.2 ⁇ g/ml .
- Retinoic acid (Sigma) was added at a concentration of 10 ° M. 10 ⁇ l of one of these regulatory factor-containing solutions was added to each proliferative factor-containing well of the 96 well plates. Control wells, containing only proliferative factors, were also prepared.
- the activin, BMP-2, TGF-/3. IL-2, IL-6, IL-8, MIP- ld, MIP- 1/3, MIP-2, TNF ⁇ and EGF additions were repeated every second day, CNTF which was added each day and retinoic acid, NGF and PDGF were added only once, at the beginning of the experiment.
- the cells were incubated for a period of 10- 12 days.
- the number of neurospheres in each well was counted and the resulting counts tabulated using Cricket Graph III. Other relevant information regarding sphere size and shape were also noted.
- bFGF had a greater proliferative effect than EGF on the numbers of neurospheres generated per well. In the presence of 20 ng/ml EGF, approximately 29 neurospheres per well were generated In the presence of bFGF, approximately 70 neurospheres were generated. However, in bFGF alone (FIG I B), the neurospheres were only about 20% of the size of those generated in the presence ot EGF (FIG. 1A). The combination of EGF and bFGF (FIG I C) produces significantly more neurospheres than does EGF alone, but fewer than seen w ith bFGF alone. The neurospheres are larger than those seen in bFGF alone, approximating those seen in EGF.
- TGF ⁇ family interleukins, macrophage-inhibitory proteins, PDGF, TNF ⁇ , retinoic acid ( 10 ⁇ M) and CNTF significantly reduced the numbers of neurospheres generated in all of the proliferative factors or combinations of proliferative factors tested.
- BMP-2 (at a dose of 10 ng/ml), completely abolished neurosphere proliferation in response to EGF.
- EGF and heparan sulfate both greatly increased the size of the neurospheres formed in response to bFGF (about 400%).
- TGF3 Family* -57% 57% . -34% .. -55% - -20% _
- Numbers of neurospheres generated are given as percentages that reflect the decrease (-) or increase (+) in numbers of neurospheres per well, in response to a PROLIFERATIVE FACTOR in the presence of a REGULATORY FACTOR, compared with the number of neurospheres proliferated in the absence of the REGULATORY FACTOR
- Antisense/sense experiments Embryonic tissue was prepared as outlined in Example 1 and plated into 96 well plates in Complete Medium. Antisense and sense experiments were carried out using the following oligodeoxynucleotides (all sequences written 5' to 3'):
- EGF receptor Sense strand: GAGATGCGACCCTCAGGGAC
- Antisense strand GTCCCTGAGGGTCGCATCTC
- EGF Sense strand: TAAATAAAAGATGCCCTGG
- Antisense strand CCAGGGCATCTTTTATTTA
- Each oligodeoxynucleotide was brought up and diluted in ddH 2 0 and kept at -20°C. Each well of the 96 well plates received 10 / J of oligodeoxynucleotide to give a final concentration of either 1 , 2, 3, 4, 5, 10 or 25 ⁇ M. Oligodeoxynucleotides were added every 24 hours.
- the EGF receptor (EGFr) and EGF oligodeoxynucleotides were applied to cultures grown in bFGF (20 ng/ml), and EGFr oligodeoxynucleotides were applied to cultures grown in EGF (20 ng/ml). Cells were incubated at 37°C, in a 5 % CO ?
- FGF receptor Sense strand: GAACTGGGATGTGGGGCTGG
- Antisense strand CCAGCCCCACATCCCAGTTC
- FGF Sense strand: GCCAGCGGCATCACCTCG
- FGFr FGF receptor
- FGF oligodeoxynucleotides are applied to cultures grown in EGF
- FGFr oligodeoxynucleotides are applied to cultures grown in bFGF.
- Embryonic tissue is prepared as outlined in Example 1 and plated into 96 well plates. Complete Medium, containing 20 ng/ml of either EGF of bFGF is added to each well. 10 ⁇ l of diluted phorbol 12-myristate 13 acetate (PMA) is added once, at the beginning of the experiment, to each well of the 96 well plates, using an Eppendorf repeat pipetter with a 500 ⁇ l tip to give a final concentration of either 10, 20, 40, 100 or 200 ⁇ g/ml. Cells are incubated at 37°C in a 5% CO 2 100% humidity incubator. After a period of 10 to 12 days the number of neurospheres per well is counted and tabulated.
- PMA diluted phorbol 12-myristate 13 acetate
- Embryonic tissue is prepared as outlined in Example 1 and plated into 96 well plates. 10 ⁇ l of diluted staurosporine is added to each well of a 96 well plate, using an Eppendorf repeat pipetter with a 500 ⁇ l tip to give a final concentration of either 10, 1 , 0J , or 0.001 ⁇ M of staurosporine. Cells are incubated at 37°C, in a 5 % CO 2 100% humidity incubator. After a period of 10 to 12 days, the number of neurospheres per well is ⁇ mmed and tabulated
- Example 4 Adult spinal cord ste cell proliferation — in vitro responses to specific biological factors or combinations of factors
- the tissue was oxygenated, stirred and heated at 30°C tor 1 1/2 hours, then transferred to a vial for treatment with a trypsin inhibitor in media solution (DMEM/12/hormone mix).
- media solution DMEM/12/hormone mix
- the tissue was triturated 25-50 times with a fire narrow polished pipette.
- the dissociated cells were centrifuged at 400 r.p.m. for 5 minutes and then resuspended in fresh media solution. Cells were plated in 35 mm dishes (Costar) and allowed to settle. Most of the media was aspirated and fresh media was added.
- EGF alone, or EGF and bFGF were added to some of the dishes to give a final concentration of 20 ng/ml each, and bFGF (20 ng/ml) was added, together with 2 ⁇ g/ml of heparan sulfate, to the remainder of the dishes.
- the cells were incubated in 5 % C0 2 , 100% humidity, at 37°C for 10-14 days. The numbers of neurospheres generated per well were counted and the results tabulated.
- EGF alone resulted in the generation of no neurospheres from any of the spinal cord regions.
- neurospheres were generated from all regions of the spinal cord, in particular the lumbar sacral region.
- EGF -I- FGF and FGF + heparan sulfate produced similar numbers of spheres in the cervical region, whereas the combination of bFGF plus heparan sulfate resulted in fewer neurospheres from the thoracic and lumbar regions (see FIG. 3).
- First-passage neurospheres were obtained from adult human tissue. Du ⁇ ng a routine biopsy, normal tissue was obtained from a 65 year old female patient. The biopsy site was the right frontal lobe, 6 mm from the tip of the frontal/anterior horn of the lateral ventricle. The tissue was prepared using substantially the same procedure outlined in Example 4 using aCSF. The stem cells were cultured in T25 flasks (Nunclon) in Complete Medium with 20 ng/ml EGF. 20 ng/ml bFGF, or 20 ng/ml each EGF plus bFGF. The flasks were examined every 2-3 days for neurosphere formation. More neurospheres were generated from the combination of EGF plus EGF than with either EGF or FGF alone.
- the cannula is implanted, using a stereotaxis, into the 4th ventricle at AP -6.0 mm posterior to bregma, L -0.3 mm and DV -4.3 mm below dura, with a flat skull position between lambda and bregma.
- the cannula is secured with dental acrylic cement.
- the composition comprising a regulatory factor that inhibits stem cell proliferation in response to an injury stimulus is infused for 1-28 days at a flow rate of 0.5 ⁇ l/h.
- the composition comprises 0.9% saline, 1 mg/ml mouse serum albumin (Sigma), and BMP-2 at 10 ng/ml.
- the cannula is implanted, using a stereotaxis.
- the cannula is secured with dental acrylic cement.
- Factors which inhibit stem cell proliferation in response to an injury stimulus are infused for 1 -28 days at a flow rate of 0.5 ⁇ l/h.
- the vehicle solution is 0.9% saline, containing 1 mg/ml mouse serum albumin (Sigma).
- Inhibitory factors include those found to have an inhibitory effect on neural stem cell proliferation in vitro, such as BMP-2, CNTF, retinoic acid, members of the TGF- ⁇ and MIP family, and antisense oligodeoxynucleotides against EGF and FGF receptors.
- the response of cells in the region of the injury is determined as outlined in Example 7.
- mice are injected with bromodeoxyuridine (BrdU; Sigma, 120 mg/kg, i.pJ every two hours for a total ol 5 injections, to label proliferating cells in the region of the injury.
- Animals are sacrificed 30 minutes, 2 days, 4 days, 1 week, 6 weeks or 6 months following the final injection by an anesthetic overdose and are transcardially perfused with 4% paraformaldehyde.
- the region adjacent to and including the injury site and ventricular region adjacent to the injury site is removed and postfixed overnight at 4°C in perfusing solution, then cryoprotected. 30 ⁇ m sagittal crvostat sections are cut and directly mounted on gelled slides.
- the tissue is processed for lmmunocytochemistry after first treating the sections w ith 1 M HCI for 30 minutes at 65°C to denature cellular DNA.
- Rat anti-BrdU (Seralab) is utilized with donkey anti-rat-FITC for immiinocytocheinistrs
- Antiserum to GFAP (expressed by astrocytes) is used followed by a donkey anti-mouse-FITC to visualize GFAP expression and glial scar production.
- the effect of treatment on nestin expression is quantitated by labeling sections with an antiserum to nestin followed by a donkey anti-mouse-FITC and counting the number of nestin- immunoreactive cells near the ventricular area and the lesion site. Specificity of immunostaining is confirmed by the absence of primary antibody. Results in treated animals are compared to controls which received intraventricular treatment with the vehicle only.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US338730 | 1982-01-11 | ||
US33873094A | 1994-11-14 | 1994-11-14 | |
PCT/CA1995/000637 WO1996015226A1 (en) | 1994-11-14 | 1995-11-14 | Regulation of neural stem cell proliferation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0792350A1 true EP0792350A1 (en) | 1997-09-03 |
Family
ID=23325929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95936393A Withdrawn EP0792350A1 (en) | 1994-11-14 | 1995-11-14 | Regulation of neural stem cell proliferation |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0792350A1 (no) |
JP (1) | JPH10509592A (no) |
KR (1) | KR970707272A (no) |
CN (1) | CN1170435A (no) |
AU (1) | AU716811B2 (no) |
FI (1) | FI971956A (no) |
NO (1) | NO972171L (no) |
WO (1) | WO1996015226A1 (no) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9518606D0 (en) * | 1995-09-12 | 1995-11-15 | Inst Of Psychiatry | Neural transplantation |
GB2306481A (en) | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
US7544511B2 (en) | 1996-09-25 | 2009-06-09 | Neuralstem Biopharmaceuticals Ltd. | Stable neural stem cell line methods |
EP0941109A1 (en) * | 1996-11-15 | 1999-09-15 | Neurospheres Holdings Ltd. | Pretreatment with growth factors to protect against cns damage |
US5968829A (en) * | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
US6093531A (en) * | 1997-09-29 | 2000-07-25 | Neurospheres Holdings Ltd. | Generation of hematopoietic cells from multipotent neural stem cells |
US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
US6171610B1 (en) | 1998-04-24 | 2001-01-09 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
US5958767A (en) * | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
SE9804064D0 (sv) | 1998-11-25 | 1998-11-25 | A & Science Invest Ab | Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
US6238922B1 (en) | 1999-02-26 | 2001-05-29 | Stemcells, Inc. | Use of collagenase in the preparation of neural stem cell cultures |
GB9907243D0 (en) | 1999-03-29 | 1999-05-26 | Reneuron Ltd | Therapy |
US6465215B1 (en) | 1999-12-14 | 2002-10-15 | Reneuron Limited | Identification of cells for transplantation |
ATE473751T1 (de) | 2000-02-11 | 2010-07-15 | Schepens Eye Res Inst | Isolierung und transplantation von retinalen stammzellen |
DE60137437D1 (de) * | 2000-10-05 | 2009-03-05 | Takeda Pharmaceutical | Promotoren zur proliferation und differenzierung von stammzellen und/oder vorstufen von neuronenzellen |
WO2003024472A2 (en) | 2001-09-14 | 2003-03-27 | Stem Cell Therapeutics Inc. | Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof |
US7129034B2 (en) | 2001-10-25 | 2006-10-31 | Cedars-Sinai Medical Center | Differentiation of whole bone marrow |
JP4623967B2 (ja) * | 2002-01-14 | 2011-02-02 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 幹細胞の移動および増殖を促進するための修飾されたピリミジン化合物の使用 |
US7704737B2 (en) | 2002-07-30 | 2010-04-27 | Stem Cell Therapeutics Inc. | Oligodendrocyte production from multipotent neural stem cells |
KR100495532B1 (ko) * | 2002-09-18 | 2005-06-14 | 에프씨비파미셀 주식회사 | 간엽 간세포를 신경세포로 분화 및 증식시키는 방법 |
US8293488B2 (en) | 2002-12-09 | 2012-10-23 | Neuralstem, Inc. | Method for screening neurogenic agents |
US20040185429A1 (en) | 2002-12-09 | 2004-09-23 | Judith Kelleher-Andersson | Method for discovering neurogenic agents |
AU2003273118B2 (en) | 2003-10-29 | 2007-05-17 | Hyun-Soo Kim | Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease |
JP4597538B2 (ja) * | 2004-02-03 | 2010-12-15 | 独立行政法人産業技術総合研究所 | 神経幹細胞増殖助剤及びこれを含んだ神経幹細胞用培地 |
AU2005211847B2 (en) | 2004-02-13 | 2011-02-24 | Stem Cell Therapeutics Corp. | Use of luteinizing hormone (LH) and chorionic gonadotropin (hCG) for proliferation of neural stem cells and neurogenesis |
GB0505510D0 (en) * | 2004-06-09 | 2005-04-27 | Univ Edinburgh | Neural stem cells |
DK1758986T3 (en) * | 2004-06-09 | 2016-01-18 | Univ Edinburgh | Neural stem cells |
DE602005002430T2 (de) | 2004-09-30 | 2008-06-19 | Reneuron Ltd., Guildford | Zelllinie |
RU2434636C2 (ru) | 2004-11-17 | 2011-11-27 | Ньюралстем, Инк. | Трансплантация нервных клеток для лечения нейродегенеративных состояний |
US8287853B2 (en) | 2005-02-11 | 2012-10-16 | Agency For Science, Technology And Research | Methods of culturing mesenchymal stem cells |
SG148171A1 (en) * | 2005-02-11 | 2008-12-31 | Agency Science Tech & Res | Methods of proliferating stem cells |
KR20080074108A (ko) | 2005-09-27 | 2008-08-12 | 스템 셀 테라퓨틱스 코포레이션 | 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식 |
CN1966080B (zh) * | 2005-11-17 | 2011-06-08 | 李凌松 | 一种治疗老年痴呆症、帕金森病的神经干细胞注射液 |
KR20080106976A (ko) | 2006-03-17 | 2008-12-09 | 스템 셀 테라퓨틱스 코포레이션 | 신경 줄기 세포 증식제 및 신경 줄기 세포 분화제의 연속 투여 방법 |
KR20080068352A (ko) * | 2007-01-19 | 2008-07-23 | 재단법인서울대학교산학협력재단 | 생체외 모델에 의한 신경재생물질 탐색 방법 |
JP2009278873A (ja) * | 2008-05-19 | 2009-12-03 | Japan Health Science Foundation | 培地および培養方法 |
US20100158878A1 (en) | 2008-12-23 | 2010-06-24 | Alexandra Capela | Target populations of oligodendrocyte precursor cells and methods of making and using same |
CN102762720B (zh) | 2009-11-12 | 2015-03-11 | Vbi技术有限责任公司 | 类孢子细胞子群及其用途 |
AU2011282642B2 (en) | 2010-07-28 | 2015-06-11 | Shinn-Zong Lin | Methods for treating and/or reversing neurodegenerative diseases and/or disorders |
CN102839154A (zh) * | 2011-06-23 | 2012-12-26 | 上海安集协康生物技术有限公司 | 神经干细胞培养扩增方法及所用培养基 |
CA2864818C (en) | 2012-02-17 | 2022-05-03 | The Schepens Eye Research Institute | Phenotype profile of human retinal progenitor cells |
US20170248581A1 (en) * | 2014-10-07 | 2017-08-31 | NuTech Medical, Inc. | Mesenchymal Stem Cell Diagnostic Testing |
EP3209306B1 (en) | 2014-10-20 | 2024-04-24 | Neuralstem, Inc. | Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof |
CN104726407B (zh) * | 2014-11-24 | 2021-03-16 | 斯坦姆(天津)生物技术研究有限公司 | 一种利用器官培养以增加成年神经组织中神经干细胞收获率的方法 |
CN105647868B (zh) * | 2014-12-04 | 2020-03-31 | 中国科学院大连化学物理研究所 | 一种利用表面微结构激活星形神经胶质细胞的方法 |
JP6912789B2 (ja) * | 2016-03-16 | 2021-08-04 | 株式会社日本触媒 | 神経幹細胞の培養方法、およびニューロスフェロイドの形成方法 |
CN106497879A (zh) * | 2016-11-07 | 2017-03-15 | 广州赛莱拉干细胞科技股份有限公司 | 一种神经干细胞增殖和诱导其分化为多巴胺能神经元的培养基以及应用和增殖诱导方法 |
CN108070558B (zh) * | 2017-11-24 | 2022-01-28 | 吉林省拓华生物科技有限公司 | 一种临床级神经干细胞的制备方法 |
US20210395681A1 (en) * | 2018-10-11 | 2021-12-23 | Ichimaru Pharcos Co., Ltd. | Culture medium for growth of neural stem cells |
CN112779209B (zh) * | 2019-11-08 | 2023-01-24 | 合肥中科普瑞昇生物医药科技有限公司 | 原代乳腺上皮细胞培养基、培养方法及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5100668A (en) * | 1988-06-14 | 1992-03-31 | Massachusetts Institute Of Technology | Controlled release systems containing heparin and growth factors |
CA2113118C (en) * | 1991-07-08 | 2002-09-17 | Samuel Weiss | Novel growth factor-responsive progenitor cells which can be proliferated in vitro |
US5175103A (en) * | 1991-10-21 | 1992-12-29 | Trustees Of University Of Pennsylvania | Preparation of pure cultures of post-mitotic human neurons |
AU4995193A (en) * | 1992-08-04 | 1994-03-03 | Regeneron Pharmaceuticals, Inc. | Method of enhancing differentiation and survival of neuronal precursor cells |
CA2147162C (en) * | 1992-10-16 | 2002-04-30 | Samuel Weiss | Remyelination using neural stem cells |
DE69334344D1 (de) * | 1992-10-28 | 2010-11-18 | Neurospheres Holding Ltd | Biologische Faktoren und neuronale Stammzellen |
JP3583778B2 (ja) * | 1993-01-29 | 2004-11-04 | ニューロスフィアーズ ホウルディングス リミテッド | 神経幹細胞の遺伝子修飾 |
DK0728194T3 (da) * | 1993-11-09 | 2003-04-22 | Neurospheres Holdings Ltd | In situ modifikation og manipulation af stamceller fra centralnervesystemet. |
-
1995
- 1995-11-14 JP JP8515600A patent/JPH10509592A/ja not_active Ceased
- 1995-11-14 EP EP95936393A patent/EP0792350A1/en not_active Withdrawn
- 1995-11-14 CN CN95196842A patent/CN1170435A/zh active Pending
- 1995-11-14 AU AU38367/95A patent/AU716811B2/en not_active Ceased
- 1995-11-14 WO PCT/CA1995/000637 patent/WO1996015226A1/en not_active Application Discontinuation
- 1995-11-14 KR KR1019970703245A patent/KR970707272A/ko not_active Application Discontinuation
-
1997
- 1997-05-07 FI FI971956A patent/FI971956A/fi unknown
- 1997-05-12 NO NO972171A patent/NO972171L/no not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9615226A1 * |
Also Published As
Publication number | Publication date |
---|---|
KR970707272A (ko) | 1997-12-01 |
AU716811B2 (en) | 2000-03-09 |
FI971956A0 (fi) | 1997-05-07 |
WO1996015226A1 (en) | 1996-05-23 |
FI971956A (fi) | 1997-07-04 |
CN1170435A (zh) | 1998-01-14 |
NO972171L (no) | 1997-07-07 |
AU3836795A (en) | 1996-06-06 |
MX9703492A (es) | 1997-10-31 |
JPH10509592A (ja) | 1998-09-22 |
NO972171D0 (no) | 1997-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU716811B2 (en) | Regulation of neural stem cell proliferation | |
DiCicco-Bloom et al. | NT-3 stimulates sympathetic neuroblast proliferation by promoting precursor survival | |
CA2307017C (en) | Erythropoietin-mediated neurogenesis | |
JP4023822B2 (ja) | ドーパミン作動性細胞のインビトロ誘導 | |
CA2175992C (en) | In situ modification and manipulation of stem cells of the central nervous system | |
CA2155024C (en) | Genetic modification of neural stem cells | |
US7115418B2 (en) | Methods of proliferating undifferentiated neural cells | |
US20070111932A1 (en) | Method of enhancing and/or inducing neuronal migration using erythropoietin | |
AU2118501A (en) | Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain | |
US20020197238A1 (en) | Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells | |
AU2002308471A1 (en) | Neural progenitor cells | |
CA2492434A1 (en) | Method of enhancing and/or inducing neuronal migration using erythropoietin | |
MXPA97003492A (en) | Regulation of proliferation of cells germinal neural | |
CA2204630A1 (en) | Regulation of neural stem cell proliferation | |
MXPA97003493A (en) | In vitro induction of dopaminergi cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970522 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20030925 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040306 |